<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40369">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02147223</url>
  </required_header>
  <id_info>
    <org_study_id>BRANDED</org_study_id>
    <nct_id>NCT02147223</nct_id>
  </id_info>
  <brief_title>Sex-dependent Effects of Flavanols on Vascular Status</brief_title>
  <official_title>Sex-dependent Effects of Flavanol Metabolism and Absorption on Vascular Status</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Epidemiological studies suggest that certain foods rich in flavanols, including cocoa
      products, red wine, and tea, are associated with decreased cardiovascular mortality and
      morbidity. Dietary interventional studies have corroborated this finding and showed that
      flavanols can acutely and after sustained ingestion improve surrogate markers of
      cardiovascular risk including endothelial function. Endothelial dysfunction is the key event
      in the development and progression of cardiovascular disease. The aim of the study is to
      assess sex specific effects of cocoa flavanols on endothelial and vascular function in
      healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Absolute change of Flow-mediated Vasodilation (FMD)</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by SphygmoCor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Augmentation index</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by SphygmoCor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ambulatory blood pressure</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>automatical measurements</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma flavanol metabolites</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Measured by HPLC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>laboratory safety parameters</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>blood/urine samples for safety assessment (haematology, biochemistry, and urinalysis)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Flavanol rich product A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>250 mg flavanols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flavanol rich product B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>500 mg flavanols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flavanol rich product C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>750 mg flavanols</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Flavanol free product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>flavanol free</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flavanol rich intervention</intervention_name>
    <description>Flavanol intervention products (250 mg, 500 mg and 750 mg flavanols)</description>
    <arm_group_label>Flavanol rich product A</arm_group_label>
    <arm_group_label>Flavanol rich product B</arm_group_label>
    <arm_group_label>Flavanol rich product C</arm_group_label>
    <arm_group_label>Flavanol free product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Flavanol free intervention</intervention_name>
    <description>Calorically, micro- and macronutrient matched control product free of flavanols</description>
    <arm_group_label>Flavanol rich product A</arm_group_label>
    <arm_group_label>Flavanol rich product B</arm_group_label>
    <arm_group_label>Flavanol rich product C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy post-menopausal femal subjects (&gt;50 years)

          -  healthy male subjects (&gt;50 years)

        Exclusion Criteria:

          -  acute inflammation

          -  cardiac arrhythmia

          -  renal failure

          -  heart failure (NYHA II-IV)

          -  diabetes mellitus

          -  CRP &gt; 1 mg/dl

          -  malignant disease
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Heiss, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Cardiology, Pulmonology and Vascular Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ana Rodriguez Mateos, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Cardiology, Pulmonology and Vascular Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Malte Kelm, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Cardiology, Pulmonology and Vascular Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Heiss, MD</last_name>
    <phone>00492118118800</phone>
    <email>christian.heiss@med.uni-duesseldorf.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rabea Wagstaff, B.Sc., M.A.</last_name>
    <phone>00492118118800</phone>
    <email>rabea.wagstaff@med.uni-duesseldorf.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Cardiology, Pulmonology and Vascular Medicine</name>
      <address>
        <city>Duesseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Heiss, MD</last_name>
      <phone>00492118118800</phone>
      <email>christian.heiss@med.uni-duesseldorf.de</email>
    </contact>
    <contact_backup>
      <last_name>Rabea Wagstaff, B.Sc., M.A.</last_name>
      <phone>00492118118800</phone>
      <email>rabea.wagstaff@med.uni-duesseldorf.de</email>
    </contact_backup>
    <investigator>
      <last_name>Christian Heiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ana Rodriguez Mateos, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberto Sansone, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.uniklinik-duesseldorf.de/unternehmen/kliniken/klinik-fuer-kardiologie-pneumologie-und-angiologie/</url>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 22, 2014</lastchanged_date>
  <firstreceived_date>May 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heinrich-Heine University, Duesseldorf</investigator_affiliation>
    <investigator_full_name>Klinik für Kardiologie, Pneumologie und Angiologie</investigator_full_name>
    <investigator_title>Klinik für Kardiologie, Pneumologie und Angiologie</investigator_title>
  </responsible_party>
  <keyword>flavanols</keyword>
  <keyword>sex-related cardiovascular effects</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
